Related Experiment Video
Updated: Feb 3, 2026

Intravital Microscopy of Monocyte Homing and Tumor-Related Angiogenesis in a Murine Model of Peripheral Arterial Disease
Published on: August 26, 2017
[Antithrombotic therapy in patients with peripheral artery diseases]
A V Svetlikov1, S V Sapelkin2, L É Ishpulaeva3
1Clinical Hospital No122 named after L.G. Sokolov under the Federal Biomedical Agency of the Russian Federation, Saint Petersburg, Russia; North-Western State Medical University named after I.I. Mechnikov under the RF Ministry of Public Health, Saint Petersburg, Russia.
Insights
Atherothrombosis complications, including peripheral artery disease (PAD), are leading causes of death. Current antithrombotic therapies like aspirin are standard for PAD, but optimizing treatment after revascularization remains challenging.
Area of Science:
- Cardiovascular Medicine
- Vascular Surgery
- Thrombosis Research
Background:
- Atherothrombosis is a primary driver of cardiovascular disease mortality globally.
- Peripheral artery disease (PAD) significantly worsens patient prognosis and increases mortality risk.
- Optimizing antithrombotic therapy is crucial for managing ischemic complications in cardiovascular patients.
Purpose of the Study:
- To review current antithrombotic therapy strategies for peripheral artery disease (PAD).
- To evaluate the effectiveness of acetylsalicylic acid as a standard treatment for PAD.
- To address the complexities of selecting antithrombotic therapy post-revascularization in PAD patients.
Main Methods:
- Literature review of antithrombotic therapies for PAD over the past two decades.
- Analysis of treatment guidelines and clinical trial data for acetylsalicylic acid.
- Examination of challenges and emerging strategies for antithrombotic therapy post-revascularization.
Main Results:
- Acetylsalicylic acid remains the established standard antithrombotic therapy for PAD.
- Despite its use, ischemic complications persist as a significant concern in PAD patients.
- Selecting optimal antithrombotic regimens after revascularization presents ongoing clinical challenges.
Conclusions:
- Current antithrombotic strategies, while including aspirin, necessitate further refinement for PAD.
- Improved antithrombotic approaches are needed to reduce ischemic events, particularly after revascularization.
- Further research is essential to personalize and enhance antithrombotic therapy in cardiovascular disease management.
Abstract:
Complications of cardiovascular diseases whose substrate is atherothrombosis continue to occupy leading positions in the structure of mortality worldwide. Peripheral artery diseases (PAD), in particular, are characterized by an especially unfavourable life prognosis for patients with cardiovascular diseases. In order to decrease the risks of ischaemic complications in patients with PAD, various approaches to antithrombotic therapy have over the last two decades been studied, with the resulting standard of therapy continuing to be acetylsalicylic acid. Even more difficult today is the task of selecting antithrombotic therapy in patients having endured revascularization.
More Related Videos
13:48Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
Published on: April 21, 2023
13:50Sequencing of Bacterial Microflora in Peripheral Blood: our Experience with HIV-infected Patients
Published on: June 11, 2011
Related Concept Videos
Peripheral Artery Disease I: Introduction
Peripheral Artery Disease IV: Nursing Management
Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease V: Postoperative Nursing Management
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Coronary Artery Disease I: Introduction